ERBB2 and neoplasm: The efficacy of DNA vaccines targeting HER2 in BALB-neuT mice [20] relies mostly on the direct activity of vaccine-elicited Abs [21–23] and is strictly dependent on the tumor stage at the time of vaccination; the sooner the vaccination is performed, the better the outcome [24].